Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
endometrial cancer, durvalumab based treatment vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 0.59 [0.42; 0.83]
DUO-E (durvalumab then durvalumab alone vs control arms), 2023 0.77 [0.56; 1.06]
0.68 [0.52 ; 0.88 ] DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023, DUO-E (durvalumab then durvalumab alone vs control arms), 2023 2 19% 957 low not evaluable progression or deaths (PFS)detailed results DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 0.55 [0.43; 0.70]
DUO-E (durvalumab then durvalumab alone vs control arms), 2023 0.71 [0.57; 0.89]
0.63 [0.49 ; 0.81 ] DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023, DUO-E (durvalumab then durvalumab alone vs control arms), 2023 2 58% 957 low not evaluable AE (any grade)detailed results DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 0.50 [0.02; 15.07]
0.50 [0.02 ; 15.07 ] DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 1 0% 474 NA not evaluable AE (grade 3-5)detailed results DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 1.59 [1.09; 2.31]
1.59 [1.09 ; 2.31 ] DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 1 0% 474 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 1.41 [0.90; 2.19]
1.41 [0.90 ; 2.19 ] DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 1 0% 474 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-25 15:00 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 77,383
- treatments: 854,374,953,672,1080,1560,1073,862
